Key result
Adriamycin linked to oxidized dextran showed higher antitumor activity, three times less acute toxicity, and a 160-fold higher AUC compared to free adriamycin in rats.
Why the study?
Does adriamycin linked to oxidized dextran improve antitumor activity and reduce toxicity compared to free adriamycin in rats?
Does adriamycin linked to oxidized dextran improve antitumor activity and reduce toxicity compared to free adriamycin in rats?
Linking adriamycin to oxidized dextran improves its therapeutic index in rats by increasing plasma exposure and reducing acute toxicity.
May improve therapeutic index via dextran conjugation in rats; leaves open translation to clinical use.
Adriamycin linked to oxidized dextran (ADM-OXD) via Schiff's base formation was compared with free adriamycin with regard to antitumor activity, acute toxicity and plasma pharmacokinetics in rats following i.v. administration. ADM-OXD showed higher activity against Walker carcinosarcoma 256 than free adriamycin. On the other hand, the acute toxicity of ADM-OXD was about three times less than that of free adriamycin. In contrast to free adriamycin, a very high plasma level of adriamycin was found after i.v. administration of ADM-OXD. The area under the plasma concentration curve with ADM-OXD was about 160-fold higher than with free adriamycin. Thus, the improvement of the therapeutic index in the case of ADM-OXD might be due to the difference in the disposition of ADM-OXD and free adriamycin in rats.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (1989) studied Walker carcinosarcoma 256. Adriamycin linked to oxidized dextran (ADM-OXD) vs. Free adriamycin was evaluated on Antitumor activity, acute toxicity, and plasma pharmacokinetics. Adriamycin linked to oxidized dextran showed higher antitumor activity, three times less acute toxicity, and a 160-fold higher AUC compared to free adriamycin in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: